European Archives - Page 90 of 1301 - European Medical Journal

Higher Cancer Risk with JAK Inhibitors in Rheumatoid Arthritis Treatment

Researchers analyzed over 6,500 treatment episodes between January 2017 and December 2020, with follow-up through June 2024

Novel Oral Polio Vaccines Show Strong Safety and Immune Response

A Phase 1 USA trial finds novel oral polio vaccines nOPV1 and nOPV3 to be safe, highly immunogenic, and comparable to Sabin-strain vaccines, paving the way for Phase 2 studies.

Real-World Data Reveals Safety Patterns of Biologics in Paediatric IBD

A large safety analysis of infliximab and adalimumab in pediatric inflammatory bowel disease highlights the need for continued postmarketing monitoring, with new concerns emerging for long-term infliximab use.

GLP-1 Receptor Agonists Show Promise in Hidradenitis Suppurativa

By Month 6 (M6), 50–60% achieved at least a one-point improvement across validated HS severity measures.

EMJ Dermatology 13 [Supplement 3] 2025

In this interview, two dermatology experts from Germany share their treatment experiences of using lebrikizumab to treat patients with…

The Evolving Atopic Dermatitis Treatment Landscape

Experts provide real-life insights and case examples of managing moderate-to-severe atopic dermatitis, sharing their treatment experience with lebrikizumab.

NICE launches landmark guidance in type 2 diabetes

NICE unveils new type 2 diabetes guidance, promoting earlier access to advanced therapies such as SGLT-2 inhibitors and more.

Long COVID: Cardiovascular Patterns Revealed with Smartwatch Biometrics

Wearables reveal unique activity and heart rate patterns in long COVID, showing promise as clinical biomarkers.

Pyridostigmine Boosts Recovery in Underactive Bladder Post-TURP

Taken together, the findings suggest that targeted augmentation of cholinergic signalling may help bridge the gap between anatomical de-obstruction and functional recovery in BOO-mediated UAB.

Renal Dysfunction Persists Despite Pulmonary Hypertension Treatment

A large pooled analysis shows that kidney problems are common in PAH and CTEPH, worsen survival, and see only minor improvement with current pulmonary hypertension therapies.